PRIME MEDICINE INC. - COMMON STOCK

Prime Medicine to Participate in Upcoming Investor Conferences

28 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

20 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Prime Medicine Announces Pricing of Upsized Public Offering

14 Feb 2024 23:50:13 By Nasdaq GlobeNewswire

Prime Medicine Announces Proposed Public Offering of Common Stock

14 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

25 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

05 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at Upcoming Investor Conferences

08 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

03 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

27 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

24 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

17 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at Upcoming Investor Conferences

19 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at Upcoming Investor Conferences

31 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

07 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

22 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at Investor Conferences in June

31 May 2023 08:00:00 By Nasdaq GlobeNewswire

Prime Medicine to Present at Virtual Investor Conferences in May

17 May 2023 16:05:00 By Nasdaq GlobeNewswire

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

17 May 2023 06:00:00 By Nasdaq GlobeNewswire